Description
Celecoxib-d
7 is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC
50s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively). It displays chemopreventive activity in multiple tumor types
via proapoptotic effects that are independent of COX-2 inhibition. Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events.
References
[1] MD.JASHIM UDDIN Edward E K P N Praveen Rao. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere[J]. Bioorganic & Medicinal Chemistry, 2003, 11 23: Pages 5273-5280. DOI:
10.1016/j.bmc.2003.07.005[2] I A MARDINI G A F. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.[J]. Molecular interventions, 2001, 1 1: 30-38.
[3] VERENA JENDROSSEK Claus B René Handrick. Celecoxib activates a novel mitochondrial apoptosis signaling pathway[J]. FASEB Journal, 2003, 17 11: 1-25. DOI:
10.1096/fj.02-0947fje[4] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[5] JIUXIANG ZHU. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.[J]. Cancer research, 2004, 64 12: 4309-4318. DOI:
10.1158/0008-5472.can-03-4063
